Novo Nordisk
As of the edition of 20 October 2026, Novo Nordisk runs 60 drugs, 29 of them marketed; it is on route A at 2 targets and on route B at 8 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 5 company names in this family.
- Akero Therapeutics, Inc: acquired in 2025; successor Novo Nordisk A/S
Drugs by status
| Status | Count |
|---|---|
| Marketed | 29 |
| Active | 12 |
| Went quiet | 10 |
| Stopped | 5 |
| Status not established | 4 |
| Total | 60 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Semaglutide | Ends 2034 (patent) | 0 |
| Insulin human | Ended 1994 (computed from the first US licence) | 1 |
| Liraglutide | Ended 2025 (patent) | 0 |
| Insulin aspart | Ended 2012 (computed from the first US licence) | 0 |
| Somatropin | Ended 2003 (orphan exclusivity) | 4 |
| Estradiol | Ends 2032 (patent) | 6 |
| Insulin degludec | Ends 2027 (computed from the first US licence) | 0 |
| Insulin detemir | Ended 2017 (computed from the first US licence) | 0 |
| Glucagon | none listed | 2 |
| Eptacog alfa (activated) | Ended 2021 (orphan exclusivity) | 0 |
| Repaglinide | none listed | 4 |
| Norethindrone acetate | none listed | 3 |
| Insulin icodec | Ends 2038 (computed from the first US licence) | 0 |
| Somapacitan | Ends 2032 (computed from the first US licence) | 1 |
| Turoctocog alfa | Ended 2025 (computed from the first US licence) | 0 |
| Insulin pork | none listed | 0 |
| Catridecacog | Ended 2025 (computed from the first US licence) | 0 |
| Concizumab | Ends 2036 (computed from the first US licence) | 1 |
| Turoctocog alfa pegol | Ends 2031 (computed from the first US licence) | 0 |
| Insulin susp isophane beef | none listed | 0 |
| Nonacog beta pegol | Ends 2029 (computed from the first US licence) | 0 |
| Nedosiran sodium | Ends 2038 (patent) | 3 |
| Glucagon hydrochloride | none listed | 1 |
| Nedosiran | none listed | 3 |
| Gliquidone | none listed | 2 |
A route B row is one company at one target. 4 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 2 targets, route B at 8 targets.
All 10 rows on route A or B
In the product10 company-target rows on route A or B; 7 are not shown here, and no score is.
See all 10 targets where Novo Nordisk needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 428 trials led
- Hormones: 359 trials led
- Immune system: 62 trials led